[Form 4] Core Laboratories Inc. /DE/ Insider Trading Activity

Rhea-AI Filing Summary

Mark D. Tattoli, Senior Vice President, General Counsel & Secretary of Core Laboratories Inc. (CLB), reported insider transactions dated 10/01/2025. The filing shows a sale of 276 shares of Common Stock at $12.58 and a simultaneous award/issuance of 700 restricted shares with a $0 reported price. After these reported transactions the filing lists 16,994.621 shares beneficially owned directly and 1,694.842 shares held indirectly in a 401(k) plan.

The restricted shares vest annually over six years on each anniversary of the grant date per the award agreement. Multiple restricted-share grants are aggregated in the disclosed restricted-share total. The report is signed and dated 10/02/2025.

Insights

Corporate Governance Expert

TL;DR: Director/officer sold 276 shares and received 700 restricted shares on 10/01/2025.

The Form 4 discloses a disposition of 276 shares at $12.58, followed by an award of 700 restricted shares priced at $0, which increases reported direct holdings to 16,994.621 shares. This pattern is common when executives receive compensation in the form of restricted equity and occasionally sell small portions of their holdings.

The filing also shows 1,694.842 shares held indirectly in a 401(k) plan. The restricted shares vest annually over six years, which ties a portion of compensation to continued service per the award agreement.

Executive Compensation Analyst

TL;DR: The award is time‑vested restricted stock over six years; immediate dilution is minimal.

The disclosure states restricted shares "vest annually over six years," indicating time-based retention rather than performance conditions. The reported 700 restricted shares are included in the post-transaction total of 1,450 restricted shares (aggregate across grants) per the filing footnote, showing ongoing compensation issuance.

Because the grant price is listed as $0, this represents standard restricted stock rather than a purchase option; vesting schedule will determine when these shares become freely tradable for the reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Tattoli Mark Damian

(Last) (First) (Middle)

6316 WINDFERN ROAD

(Street)

HOUSTON TX 77040

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Core Laboratories Inc. /DE/ [ CLB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Gen Counsel & Secretary

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		F		276	D	$12.58	16,718.621	D
Common Stock	10/01/2025		M		700	A	$0	16,994.621	D
Common Stock								20	I	Custodial account
Common Stock								1,694.842	I	401 (k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Shares	(1)	10/01/2025		M			700	(1)	(1)	Common Stock	700	$0	1,450(2)	D

Explanation of Responses:

1. The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date.

2. Multiple restricted share grants are included in this total.

	/s/ Mark D. Tattoli	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.